584 results on '"Targan, S"'
Search Results
2. A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis.
3. Identification of candidate bacterial pathogens in ulcerative colitis using a disease-specific marker antibody
4. OP40 PRA023 Demonstrated Efficacy and Favorable Safety as Induction Therapy for Moderately to Severely Active UC: Phase 2 ARTEMIS-UC Study Results
5. Inhibition of a novel fibrogenic factor Tl1a reverses established colonic fibrosis
6. Cathelicidin suppresses lipid accumulation and hepatic steatosis by inhibition of the CD36 receptor
7. Author Correction: Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease (Nature Communications, (2020), 11, 1, (995), 10.1038/s41467-019-14275-y)
8. New IBD markers: definition of disease heterogeneity
9. On the pathogenesis trail: what marker B cell clones tell us about IBD
10. Large-scale sequencing identifies multiple genes and rare variants associated with Crohn’s disease susceptibility
11. Antibodies to proinflammatory cytokines
12. Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus
13. P549 Effect of maintenance Ustekinumab on corticosteroid-free clinical outcomes in patients with Crohnʼs disease
14. OP010 Long term efficacy and safety of Ustekinumab for Crohnʼs disease: results from IM-UNITI long-term extension through 2 years
15. A validated web-based tool to display individualised Crohnʼs disease predicted outcomes based on clinical, serologic and genetic variables
16. Long-term outcomes of thalidomide in refractory Crohnʼs disease
17. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
18. An IFNG SNP with an estrogen-like response element selectively enhances promoter expression in peripheral but not lamina propria T cells
19. Evaluation of blends tincal waste, volcanic tuff, bentonite and fly ash for use as a cement admixture
20. Split-dose administration of thiopurine drugs: a novel and effective strategy for managing preferential 6-MMP metabolism
21. Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis – a double-blind comparison with sustained release mesalazine
22. Linkage of Crohn’s disease-related serological phenotypes: NFKB1 haplotypes are associated with anti-CBir1 and ASCA, and show reduced NF-κB activation
23. Differences in the management of Crohnʼs disease among experts and community providers, based on a national survey of sample case vignettes
24. Anti-outer membrane of porin C and anti-I2 antibodies in indeterminate colitis
25. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial
26. Crohn’s ileitis after liver transplantation from a living related donor with Crohn’s disease
27. Infliximab in the treatment of medically refractory indeterminate colitis
28. High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis
29. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease
30. Influence of natural pozzolan, colemanite ore waste, bottom ash, and fly ash on the properties of Portland cement
31. Marker antibody expression stratifies Crohnʼs disease into immunologically homogeneous subgroups with distinct clinical characteristics
32. Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease
33. Ustekinumab as induction and maintenance therapy for Ulcerative Colitis
34. Summary
35. Introduction: anti-TNF strategies in the treatment of Crohn's disease
36. Linkage of Crohn's disease to the major histocompatibility complex region is detected by multiple non-parametric analyses
37. DOP29 Elevation of a novel blood-based gene signature in a severe Crohn’s disease (CD) subtype preceding surgery defines and predicts a post-surgical decrease in pro-inflammatory pathway activation
38. Efficacy and Safety of Ustekinumab as Maintenance Therapy in Ulcerative Colitis: Week 44 Results from UNIFI
39. Efficacy in Biologic Failure and Nonbiologic-Failure Populations in a Phase 3 Study of Ustekinumab in Moderate-Severe Ulcerative Colitis: UNIFI
40. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role
41. Effects of supplementary cementing materials on the properties of cement and concrete
42. Repeated infusions of anti-TNF-alpha chimeric antibody (cA2) maintain remission in refractory Crohn's disease 39.05
43. Safety, tolerance and activity of multiple doses of subcutaneous recombinant human interleukin-10 (rHuIL-10) in patients with mild to moderate active Crohn's disease 11.02
44. Controlled study of anti-TNF-alpha treatment for enterocutaneous fistulae complicating Crohn's disease 01.11
45. P343 Efficacy of ustekinumab in Crohn’s disease at maintenance Week 56: IM-UNITI study
46. OP37 Efficacy and safety of ustekinumab as maintenance therapy in ulcerative colitis: Week 44 results from UNIFI
47. P312 Efficacy in biologic failure and non-biologic-failure populations in a Phase 3 study of ustekinumab in moderate–severe ulcerative colitis: UNIFI
48. P317 Characterisation of patients with delayed response to ustekinumab for Crohn’s disease
49. DOP54 Efficacy and safety of ustekinumab through Week 16 in patients with moderate-to-severe ulcerative colitis randomised to ustekinumab: results from the UNIFI induction trial
50. DOP47 Sustained remission in patients with moderate to severe ulcerative colitis: Results from the Phase 3 UNIFI maintenance study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.